A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants.
PMID: 34732694
2021
Signal transduction and targeted therapy
Abstract: Binding assay and pseudovirus neutralization assay show no evasion of recently prevalent SARS-CoV-2 lineages, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) for n3113.1-Fc with Y58L mutation, demonstrating the potential of n3113.1-Fc (Y58L) as a promising candidate for clinical development to treat COVID-19.
Result: Based on these findings, we tried mutations of Y52, Y58, and W49 on n3113.1 to shorten the side chains and found a single Y58L mutation could recover the binding ability of n3113.1-Fc to Delta S.
Result: In alignment with this, the Y58L mutant on n3113.1-Fc reverted susceptivity to virus pseudotyped with Delta S.
Result: The unperturbed binding potency of n3113-Fc (especially with Y58L mutation) to variant
SARS_CoV_2 mutation literature information.
PMID: 
2021
Signal transduction and targeted therapy
Browser Board
Co-occurred Entities
Filtrator